EUVIMEDEUVIMED entdecken
Klinische Studie

Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial

Catheryn Yashar, Atif J Khan, Peter Chen, John Einck, Matthew Poppe, Linna Li, Zeinab Abou Yehia, Frank A Vicini, Dirk Moore, Doug Arthur, T J Quinn, Maria Kowzun und 5 weitere

Practical Radiation Oncology · 2023

DOI: 10.1016/j.prro.2023.03.006 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Practical Radiation Oncology, 2023. Verfasst von Catheryn Yashar und 16 weiteren Autor:innen. Beteiligte Einrichtung: UC San Diego/Moores Cancer Center, La Jolla, California; Bryn Mawr Hospital, Bryn Mawr, Pennsylvania. Electronic address: cyashar@health.ucsd.edu. Hauptthemen laut MEDLINE: Brachytherapy, Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Shorter courses of breast radiotherapy are offered as an alternative to 4 weeks of whole-breast irradiation after lumpectomy, including brachytherapy. A prospective phase 2multi-institution clinical trial to study 3-fraction accelerated partial breast irradiation delivered by brachytherapy was conducted. METHODS AND MATERIALS: The trial treated selected breast cancers after breast-conserving surgery with brachytherapy applicators that delivered 22.5 Gy in 3 fractions of 7.5 Gy. The planning treatment volume was 1 to 2 cm beyond the surgical cavity. Eligible women were age ≥45 years with unicentric invasive or in situ tumors ≤3 cm excised with negative margins and with positive estrogen or progesterone receptors and no metastases to axillary nodes. Strict dosimetric parameters were required to be met and follow up information was collected from the participating sites. RESULTS: Two hundred patients were prospectively enrolled; however, a total of 185 patients who were enrolled were followed for a median of 3.63 years. Three-fraction brachytherapy was associated with low chronic toxicity. There was excellent or good cosmesis in 94% of patients. There were no grade 4 toxicities. Grade 3 fibrosis at the treatment site was present in 1.7% and 32% percent had grades 1 or 2 fibrosis at the treatment site. There was 1 rib fracture. Other late toxicities included 7.4% grade 1 hyperpigmentation, 2% grade 1 telangiectasias, 1.7% symptomatic seromas, 1.7% abscessed cavities, and 1.1% symptomatic fat necrosis. There were 2 (1.1%) ipsilateral local recurrences, 2 (1.1%) nodal recurrences and no distant recurrences. Other incidents included one contralateral breast cancer and 2 second malignancies (lung). CONCLUSIONS: Ultra-short breast brachytherapy is feasible and has excellent toxicity and could be an alternative to standard 5-day, 10 fraction accelerated partial breast irradiation in eligible patients. Patients from this prospective trial will continue to be followed to evaluate long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyBreast NeoplasmsFemaleHumansMiddle AgedFollow-Up StudiesHospitalsMastectomy, SegmentalProspective StudiesRecurrenceTreatment Outcome

Autor:innen und Institutionen

  • UC San Diego/Moores Cancer Center, La Jolla, California; Bryn Mawr Hospital, Bryn Mawr, Pennsylvania. Electronic address: cyashar@health.ucsd.edu.
  • Memorial Sloan Kettering Cancer Center, New York, New York.
  • William Beaumont Hospital/Rose Cancer Treatment Center, Royal Oak, Michigan.
  • Kansas University Medical Center, Kansas City, Kansas.
  • Hunstman Cancer Center, University of Utah, Salt Lake City, Utah.
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Zitieren

APA

Yashar, C., Khan, A. J., Chen, P., Einck, J., Poppe, M., Li, L., Yehia, Z. A., Vicini, F. A., Moore, D., Arthur, D., Quinn, T. J., Kowzun, M., Simon, L., Scanderbeg, D., Shah, C., Haffty, B. G., & Kuske, R. (2023). Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2023.03.006

Vancouver

Yashar C, Khan AJ, Chen P, Einck J, Poppe M, Li L, et al. Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial. Practical Radiation Oncology. 2023. doi:10.1016/j.prro.2023.03.006

BibTeX
@article{Yashar2023,
  author = {Yashar, Catheryn and Khan, Atif J and Chen, Peter and Einck, John and Poppe, Matthew and Li, Linna and Yehia, Zeinab Abou and Vicini, Frank A and Moore, Dirk and Arthur, Doug and Quinn, T J and Kowzun, Maria and Simon, Laurie and Scanderbeg, Daniel and Shah, Chirag and Haffty, Bruce G and Kuske, Robert},
  title = {Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial},
  journal = {Practical Radiation Oncology},
  year = {2023},
  doi = {10.1016/j.prro.2023.03.006}
}
Kostenlos starten →